Pasar al contenido principal

ANALISIS SISTEMATICO DE LA VARIACION EN LAS SECUENCIAS DE PRIONES Y SU MALPLEGAMIENTO: DE LOS DETERMINANTES MOLECULARES A LA INTERVENCION TERAPEUTICA

PID2024-160022OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para la Investigación y el Desarrollo Experimental
Subprograma Subprograma Estatal de Generación de Conocimiento Científico-Técnico y Desarrollo Experimental
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The L108I polymorphism in mouse prion protein drives spontaneous disease and enhances transmission of atypical and classical prion strains

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M
  • Díaz-Domínguez, Carlos M
  • Sampedro-Torres-Quevedo, Cristina
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Giler, Samanta
  • González-Martín, Nora
  • Lorenzo, Nuria L.
  • Manero-Azua, Africa
  • de Nanclares, Guiomar P.
  • Geijo, Mariví
  • Sánchez-Martín, Manuel A
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases are fatal neurodegenerative disorders that can be idiopathic, associated with genetic mutations, or acquired by infection with misfolded prion protein. We developed two complementary transgenic mouse models to investigate how the L108I substitution in mouse prion protein (PrP) influences spontaneous prion formation and transmission characteristics. The transgenic mouse model overexpressing the variant at approximately three times wild-type (WT) PrP levels (TgMo(L108I)3x) consistently developed a spontaneous neurodegenerative disorder between 219 and 536 days of age with 100% penetrance. This spontaneous disease exhibited biochemical and neuropathological characteristics of atypical prion disorders, featuring a distinctive 7–10 kDa protease-resistant PrP fragment and pathology comparable to small ruminants' atypical scrapie and certain forms of Gerstmann–Sträussler–Scheinker syndrome (GSS). In contrast, the knock-in model expressing the same variant at physiological levels (TgMo(L108I)1x) showed no spontaneous disease beyond 600 days, demonstrating that both the specific amino acid substitution and elevated expression levels are necessary for spontaneous prion formation. The spontaneously generated prions transmitted efficiently to models expressing the I108 variant and to Tga20 mice overexpressing WT PrP but encountered a robust transmission barrier toward WT mice, indicating strain-specific replication requirements. The TgMo(L108I)3x model demonstrated exceptional versatility as a universal acceptor for heterogeneous prion isolates, demonstrating superior efficiency in propagating atypical variants like GSS A117V (57 ± 0.6 days) and rapid propagation of classical scrapie-derived mouse prion strains, including Rocky Mountains Laboratory mouse prion strain (RML) (85 ± 3.8 days) and 22L (95 ± 1 days). Comparative analysis revealed that the L108I substitution differentially impacts strain propagation, with greater acceleration of RML (~33% shorter incubation) than 22L (~0.5% shorter) compared to WT mice. These complementary systems offer powerful experimental platforms for investigating the molecular determinants of spontaneous prion formation, strain selection and transmission barriers, providing insights into idiopathic prion pathogenesis and developing therapeutic interventions., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to Joaquín Castilla, PID2020-117465GB-I00 granted to Jesús R. Requena, and PID2021-1222010B-C22 granted to Enric Vidal, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to Joaquín Castilla, Hasier Eraña and Enric Vidal. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to Joaquín Castilla, also funded by Ministerio de Ciencia e Innovación/AEI/10.13039/501100011033. Transgenic Facility of IBSAL-University of Salamanca, directed by Manuel A. Sánchez‑Martín, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. Eva Fernández-Muñoz received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Rapid generation of prion disease models using AAV-delivered PrP variants in knockout mice

  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Charco, Jorge M.
  • Vidal, Enric
  • Herrero-Martínez, Diego
  • Galarza-Ahumada, Josu
  • Sampedro-Torres-Quevedo, Cristina
  • Giler, Samanta
  • Geijo, Mariví
  • González-Aseguinolaza, Gloria
  • Eraña, Hasier
  • Castilla, Joaquín
The study of prion biology has traditionally relied on transgenic mouse models, which, while valuable, require significant time and resources to develop. Here, we present a rapid and flexible alternative using adeno-associated virus (AAV) vectors to express modified prion proteins in PrP-knockout (PrP-KO) mice. Through systematic evaluation of multiple AAV constructs, we optimized vector design by comparing different CNS-specific promoters and regulatory elements to generate prion disease models capable of faithfully propagating the inoculated prion strain. We identified an optimized AAV construct incorporating the human synapsin promoter, MVM enhancer, and WPRE posttranscriptional regulatory element encapsidated in the AAV9P31 serotype to drive neuron-specific expression of modified mouse PrP (W144Y epitope) and bank vole I109 PrP (W145Y epitope). Following intravenous administration, we achieved brain-wide expression at levels comparable to or even exceeding endogenous PrP in some regions. When challenged with mouse-adapted RML prions or human Gerstmann-Sträussler-Scheinker (GSS-A117V) disease-causing prions, AAV-PrP mice developed characteristic signs of prion disease with accelerated kinetics (58–106 days post-inoculation for RML; 105–112 dpi for GSS-A117V), displaying features typical of each strain. Serial transmission of AAV-generated RML prions to wild-type mice confirmed preservation of strain-specific properties (165 ± 4 dpi), validating the authenticity of prion propagation in this system. This approach provides a versatile platform for rapidly generating and studying prion variants in an authentic brain environment. By reducing model generation time from months to weeks, this system enables accelerated investigation of prion structure–function relationships, strain properties, and therapeutic strategies, with potential applications extending to other protein misfolding diseases., The present work was partially funded by four grants awarded by the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (Spanish Government): grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21, and PID2021-122201OB-C22, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF); and grant EFA031/01 NEURO-COOP, co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional support was provided by the CJD Foundation (2024 grant). CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation (CEX2021-001136-S), funded by MCIN/AEI/10.13039/501100011033. Additionally, Eva Fernández-Muñoz received funding from Fundacion Tatiana Perez de Guzman el Bueno, PhD grant BN661-FTPGB-2023. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, N.
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel A.
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • di Bari, Michele
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The L108I polymorphism in mouse prion protein drives spontaneous disease and enhances transmission of atypical and classical prion strains

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M
  • Díaz-Domínguez, Carlos M
  • Sampedro-Torres-Quevedo, Cristina
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Giler, Samanta
  • González-Martín, Nora
  • Lorenzo, Nuria L.
  • Manero-Azua, Africa
  • de Nanclares, Guiomar P.
  • Geijo, Mariví
  • Sánchez-Martín, Manuel A
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases are fatal neurodegenerative disorders that can be idiopathic, associated with genetic mutations, or acquired by infection with misfolded prion protein. We developed two complementary transgenic mouse models to investigate how the L108I substitution in mouse prion protein (PrP) influences spontaneous prion formation and transmission characteristics. The transgenic mouse model overexpressing the variant at approximately three times wild-type (WT) PrP levels (TgMo(L108I)3x) consistently developed a spontaneous neurodegenerative disorder between 219 and 536 days of age with 100% penetrance. This spontaneous disease exhibited biochemical and neuropathological characteristics of atypical prion disorders, featuring a distinctive 7–10 kDa protease-resistant PrP fragment and pathology comparable to small ruminants' atypical scrapie and certain forms of Gerstmann–Sträussler–Scheinker syndrome (GSS). In contrast, the knock-in model expressing the same variant at physiological levels (TgMo(L108I)1x) showed no spontaneous disease beyond 600 days, demonstrating that both the specific amino acid substitution and elevated expression levels are necessary for spontaneous prion formation. The spontaneously generated prions transmitted efficiently to models expressing the I108 variant and to Tga20 mice overexpressing WT PrP but encountered a robust transmission barrier toward WT mice, indicating strain-specific replication requirements. The TgMo(L108I)3x model demonstrated exceptional versatility as a universal acceptor for heterogeneous prion isolates, demonstrating superior efficiency in propagating atypical variants like GSS A117V (57 ± 0.6 days) and rapid propagation of classical scrapie-derived mouse prion strains, including Rocky Mountains Laboratory mouse prion strain (RML) (85 ± 3.8 days) and 22L (95 ± 1 days). Comparative analysis revealed that the L108I substitution differentially impacts strain propagation, with greater acceleration of RML (~33% shorter incubation) than 22L (~0.5% shorter) compared to WT mice. These complementary systems offer powerful experimental platforms for investigating the molecular determinants of spontaneous prion formation, strain selection and transmission barriers, providing insights into idiopathic prion pathogenesis and developing therapeutic interventions., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to Joaquín Castilla, PID2020-117465GB-I00 granted to Jesús R. Requena, and PID2021-1222010B-C22 granted to Enric Vidal, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to Joaquín Castilla, Hasier Eraña and Enric Vidal. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to Joaquín Castilla, also funded by Ministerio de Ciencia e Innovación/AEI/10.13039/501100011033. Transgenic Facility of IBSAL-University of Salamanca, directed by Manuel A. Sánchez‑Martín, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. Eva Fernández-Muñoz received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rapid generation of prion disease models using AAV-delivered PrP variants in knockout mice

  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Charco, Jorge M.
  • Vidal, Enric
  • Herrero-Martínez, Diego
  • Galarza-Ahumada, Josu
  • Sampedro-Torres-Quevedo, Cristina
  • Giler, Samanta
  • Geijo, Mariví
  • González-Aseguinolaza, Gloria
  • Eraña, Hasier
  • Castilla, Joaquín
The study of prion biology has traditionally relied on transgenic mouse models, which, while valuable, require significant time and resources to develop. Here, we present a rapid and flexible alternative using adeno-associated virus (AAV) vectors to express modified prion proteins in PrP-knockout (PrP-KO) mice. Through systematic evaluation of multiple AAV constructs, we optimized vector design by comparing different CNS-specific promoters and regulatory elements to generate prion disease models capable of faithfully propagating the inoculated prion strain. We identified an optimized AAV construct incorporating the human synapsin promoter, MVM enhancer, and WPRE posttranscriptional regulatory element encapsidated in the AAV9P31 serotype to drive neuron-specific expression of modified mouse PrP (W144Y epitope) and bank vole I109 PrP (W145Y epitope). Following intravenous administration, we achieved brain-wide expression at levels comparable to or even exceeding endogenous PrP in some regions. When challenged with mouse-adapted RML prions or human Gerstmann-Sträussler-Scheinker (GSS-A117V) disease-causing prions, AAV-PrP mice developed characteristic signs of prion disease with accelerated kinetics (58–106 days post-inoculation for RML; 105–112 dpi for GSS-A117V), displaying features typical of each strain. Serial transmission of AAV-generated RML prions to wild-type mice confirmed preservation of strain-specific properties (165 ± 4 dpi), validating the authenticity of prion propagation in this system. This approach provides a versatile platform for rapidly generating and studying prion variants in an authentic brain environment. By reducing model generation time from months to weeks, this system enables accelerated investigation of prion structure–function relationships, strain properties, and therapeutic strategies, with potential applications extending to other protein misfolding diseases., The present work was partially funded by four grants awarded by the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (Spanish Government): grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21, and PID2021-122201OB-C22, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF); and grant EFA031/01 NEURO-COOP, co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional support was provided by the CJD Foundation (2024 grant). CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation (CEX2021-001136-S), funded by MCIN/AEI/10.13039/501100011033. Additionally, Eva Fernández-Muñoz received funding from Fundacion Tatiana Perez de Guzman el Bueno, PhD grant BN661-FTPGB-2023. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Variably protease-sensitive prionopathy: two new cases with motor neuron-dementia syndrome

  • Erro Aguirre, María Elena
  • Zelaya Huerta, María Victoria
  • Eraña, Hasier
  • Sánchez Ruiz de Gordoa, Javier
  • García Amigot, Fermín
  • Simonovska-Serra, Anika
  • Caballero Martínez, María Cristina
  • Ferrer, Isidro
  • Gelpi, Ellen
  • Jericó Pascual, Ivonne
  • Castilla, Joaquín
We describe two patients with variably protease-sensitive prionopathy (VPSPr) who developed progressive upper motor neuron symptoms, insomnia, behavioral and cognitive decline, compatible with primary lateral sclerosis associated with frontotemporal dementia (FTD). Neuropathology revealed a spongiform encephalopathy with frontotemporal and pronounced thalamic involvement, associated with fine synaptic abnormal prion protein conformer (PrPSc) deposits, microplaques, and intraneuronal aggregates. Western blot analysis revealed a characteristic VPSPr proteolytic profile, lacking the diglycosylated band. Both patients were methionine homozygous at PRNP codon 129 and carried no pathogenic mutations. These cases illustrate that VPSPr can present with a prominent motor neuron syndrome and FTD features., This work was supported by the Health Department of Navarre Government (19-2021), European Regional Development Fund, Federal Ministry Labour, Social Affairs, Health, Care and Consumer Protection, and Agencia Estatal de Investigacion, Ministerio de Ciencia e Innovacion (PID2021-122201OB-C21, PID2024-160022OB-I00), that also granted a Severo Ochoa Excellence accreditation (CEX2021-001136-S) to the CIC bioGUNE. This study was also supported by the project EFA031/01, NEURO-COOP, co-funded at 65% by the European Union (Regional Development Funds) through the Interreg VI-Spain-France-Andorra Programme (POCTEFA 2021-2027).